San Francisco, CA, 2 - 5 December 2019

Schedule

Create your personal agenda –check the favourite icon

Dec 213:00
Conference pass

Uses and clinical application of immune profiling assays for cancer:

WORKSHOP A
The use of novel assays and computational methods to analyse the immune system is a very fast-moving field and it is challenging to keep up with the pace of change. Join our Advances in Immune Profiling Assays workshop on 2nd December for an in depth look at the uses and clinical application of new methods to characterise and profile the human immune system for the accelerated development of new therapies.Topics:·Measuring base-line immune function ·Assessing predictive biomarkers for PD1 / PDL1 immunotherapies·How to assess the efficacy and longevity of cellular therapies·Characterising the tumor microenvironment·Discovery of genomic predictors and genomic alterations that promote or suppress immune response·Discovery and development of novel biomarkers
Bita Sahaf, Technical Director, Stanford CCSU; Correlatives for Parker Institute for Cancer Immunotherapy; Snr Research Scientist, Stanford Cancer Institute
Vanessa Jonsson, Assistant Research Professor, City Of Hope National Medical Center
Dec 213:00
Conference pass

Advances in adjuvant technology for vaccines:

WORKSHOP B
Vaccine adjuvants have been used successfully for decades to enhance the ability to provoke an immune response of weak antigens and improve the overall potency of vaccines. Join this workshop to explore the latest advances in novel adjuvant technology for vaccines, the value of current adjuvants and how to improve them. Topics:·Adjuvant technology and its impact on vaccine development ·Can next generation adjuvants break tolerance to assist in immune oncology?·Deploying adjuvants for special populations ·Combination adjuvants – how should they be designed and what are the risks·Adjuvating live vaccines·Use of receptor agonists in improving existing adjuvants or designing new novel adjuvants for different animal species·Precision adjuvants; tailoring immune activation for next generation vaccines

Create your personal agenda –check the favourite icon

Dec 308:40
Conference pass

Immunotherapy 2020 and beyond – what are the next frontiers?

Keynotes
  • In the last 10 years ground breaking advances and progress have been made in the treatment of cancer with immunotherapy-based approaches.
  • We have seen approvals of cancer vaccines, multiple single agent and combination checkpoint inhibitor agents in a broad range of tumor types, tissue-agnostic immunotherapy and cellular and gene therapies.
  • These agents are improving survival and providing cures in some cancer patients.
  • Several new immunotherapy advancements, opportunities and challenges are on the horizon.
Dec 309:00
Conference pass

Joint Presentation: Advances in single cell sequencing and combination of multiple omics data for developing a better understanding of response to immunotherapy and vaccines

Keynotes
Lacey Kitch, Director, Informatics, Parker Institute for Cancer Immunotherapy
Dec 310:30
Conference pass

Morning Networking Break

Keynotes
Meet the Investor Speed Networking: Meet, exchange interests and swap business cards with investors in the biotechnology sector. A great opportunity to maximize your time at the event and meet up to 10 investors in 15mins. Investor companies include:
  • Biotechnology Value Fund
  • SR One
  • Healthcare Angels
  • New Enterprise Associates (NEA) Immuno-Oncology
  • Illumina Vantures
  • Medpro Investors
Dec 311:30
Conference pass

Chair’s Opening Remarks

New Technology
Dec 311:40
Conference pass

Development and validation of biomarkers for diagnosis and prediction of response resistance to treatment

Immune Profiling
Dec 311:40
Conference pass

Should each patient’s immune system inform their immunotherapy?

Cancer Immunotherapy
  • ATLAS™, an autologous immune assay that identifies specific immunogenic neoantigens, is more effective at identifying immunogenic CD4 AND CD8 targets than algorithms
  • High variability between patients shows that each individual’s immune system evolves differently throughout their lives
  • Immunosuppressive peptides, identified only through ATLAS, can undercut immunity and compromise immune function
Dec 311:40
Conference pass
Dec 312:10
Conference pass

Understanding response and resistance to checkpoint inhibitor therapy and strategies to overcome it

Immune Profiling
Dec 312:10
Conference pass

Improved identification, prediction and prioritization of cancer vaccine candidates

Cancer Immunotherapy
Dec 312:10
Conference pass

RosettaAntibodyDesign - a platform for computational antibody design

New Technology
Dec 312:40
Conference pass

Artificial Intelligence to the rescue: towards personalized, neoantigen-targeted immunotherapeutics

Cancer Immunotherapy
Dec 312:40
Conference pass

Introducing a new bioparticle platform; design, polyvalence, production and immunomodulatory potential

New Technology
Dec 312:40
Conference pass

Update on the development and use of a single-dose live oral cholera vaccine

Vaccine Development
Sean Bennett, Senior Director Of Clinical Development and Medical Affairs, Emergent BioSolutions
Dec 312:55
Conference pass

Development of EcoCRM®, a new GMP CRM197 carrier protein

New Technology
Dec 313:10
Conference pass

Networking lunch and poster session

Keynotes
Innovation & Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area. Start-up companies include; Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies
Dec 314:10
Conference pass

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types

Cancer Immunotherapy
  • Development of new paradigm shifting cancer immune-therapies
  • translational strategies from basic preclinical studies to clinical trials
  • detailed pipeline/ portfolio of validated B-cell peptide vaccines
  • Development of combinatorial immunotherapeutic strategies
Dec 314:10
Conference pass

Targeting highly conserved influenza virus epitopes with self-assembled peptides

New Technology
  • A new vaccine platform is being developed that targets B cell epitopes derived from host and microbial proteins.
  • Peptides synthesized with epitopes from the viral M2e, neuraminidase, and hemagglutinin stem proteins induce protective antibody responses in challenged mice.
  • These results suggest a path forward for the development of a universal influenza vaccine.
Dr Chris Clegg, President, Founder and Chief Scientific Officer, TRIA Bioscience
Dec 314:10
Conference pass

Development of a bioconjugate vaccine against E. coli

Vaccine Development
Dec 314:40
Conference pass

Pfizer’s vaccine immunotherapy combination regimen for cancer

Cancer Immunotherapy
Dec 314:40
Conference pass

Vaccine development in Chikungunya, a severe disease with debilitating long-term effects and global outbreak potential

New Technology
Dec 314:40
Conference pass

Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse

Vaccine Development
Dec 315:10
Conference pass

Overview of Immune Epitope Database

Immune Profiling
Overview of Immune Epitope Database
  • What does the IEDB do?
  • How to access data
  • Predictive tools
  • How does this integrate into other databases?
Dec 315:10
Conference pass

Panel: Novel approaches for the delivery of oncolytic viruses and genes

Cancer Immunotherapy
Dec 315:10
Conference pass

Preclinical development of peptide-based checkpoint agonists that enhance vaccine immunogenicity

New Technology
Dec 315:10
Conference pass

Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus

Vaccine Development
Dec 315:40
Conference pass

Susceptible or Immune? A CMV T cell assay accurately predicts patient status

Immune Profiling
  • Cellular immunity is key to controlling many viral infections, particularly in high risk populations.
  • A flow cytometry based, intracellular cytokine detection method has been developed and validated to measure CD4 and CD8 T cell responses to CMV antigen.
  • Clinical studies have demonstrated strong sensitivity, specificity, positive predictive values and negative predictive values for CMV viremia and disease.
Dec 316:40
Conference pass

Induction of innate immunity against bacterial infection

Immune Profiling
Dec 316:40
Conference pass

Immulytic; achieving personalized systemic neoantigen vaccination directly in the patient

Cancer Immunotherapy
Praveen Bommareddy, Transnational Research Lead, Replimune
Dec 316:40
Conference pass
Dec 317:10
Conference pass

Developing and utilizing positional scanning combinatorial libraries for T-lymphocyte antigen discovery

Immune Profiling
  • General concepts and illustration of positional scanning combinatorial libraries composed of trillions of peptides
  • T cell driven antigen identification approach integrates the screening results of positional scanning libraries and protein databases
  • Examples of the elucidation of the peptide and antigen specificity of T cells with unknown specificity
Dec 317:10
Conference pass

Advantages of HSV-based oncolytic virus therapies for the treatment of solid tumors

Cancer Immunotherapy
Andreas Niethammer, Senior Vice President, Head of Clin Development, Immunotherapy Solid Tumors, Sorrento Therapeutics Inc
Dec 317:10
Conference pass
Dec 317:40
Conference pass

Human in vitro modeling to inform precision vaccines for vulnerable populations

Immune Profiling
Dec 317:40
Conference pass

Armed and dangerous against cancer: TGF-beta trap and personalized oncolytic adenoviruses

Cancer Immunotherapy
  • Positive clinical data from first two patients treated with personalized i.e., neoantigen enhanced oncolytic adenoviruses
  • Data from TGF-beta trap virus, which is only months away from a Phase 1 trial, that shows abscopal anticancer activity and evidence of cold-to-hot tumor transformation
  • Biodistribution data from intravenous and intratumoral administration of the TGF-beta trap virus, which demonstrates persistent non-negligible serum levels of the TGF-beta trap
Dec 317:40
Conference pass

Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis

Vaccine Development

Create your personal agenda –check the favourite icon

Dec 408:30
Conference pass

Chairs Opening Remarks:

Cancer Antibodies and Small Molecules and Combinations
Dec 408:40
Conference pass

Pre-clinical toxicology considerations for vaccine development

Clinical Development
Dec 408:40
Conference pass

Recurrent Stage 4 Cancer: A patient’s journey and hope for the future

Cancer Antibodies and Small Molecules and Combinations
Dr Chester Kitchen, Cancer Patient Advocate, Cancer Patient Advocate
Dec 408:40
Conference pass

Opportunities and challenges for integrating delivery technologies into cancer immunotherapy

Immunotherapy Bioprocessing, Manufacture & Delivery
Michael Mitchell, Professor, University of Pennsylvania
Dec 409:10
Conference pass

Novel correlates of protection against pandemic influenza

Clinical Development
Dec 409:10
Conference pass

Combinations and checkpoint inhibitors; what’s working?

Cancer Antibodies and Small Molecules and Combinations
  • Landscape of combination therapies – why aren’t they working?
  • PD1 resistance – what are the major mechanisms we need to focus on?
Dec 409:40
Conference pass

Broader protective influenza vaccine

Vaccine Development
Dec 409:40
Conference pass

Engineering bispecific IgM antibodies as cancer therapeutics

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 410:10
Conference pass

Protection against Respiratory Syncytial Virus (RSV) by maternal immunization

Vaccine Development
Kathrin Jansen, Senior Vice President And Chief Scientific Officer, Pfizer
Dec 410:10
Conference pass
Dec 410:10
Conference pass

Overcoming the immunosuppressive TME by targeting Myeloid-Derived Suppressor Cells

Cancer Antibodies and Small Molecules and Combinations
Dec 410:10
Conference pass

Design & manufacture of next generation biotherapeutics with a scalable biochemical protein synthesis platform

Immunotherapy Bioprocessing, Manufacture & Delivery
  • Introduction to Sutro’s proprietary Cell Free Protein Expression Technology.
  • How the rapid cycle time of the CF reaction allows for high throughput screening of designed structural variants, including incorporation of non-natural amino acids, to enable development of optimal proteins for both function and manufacturability.
  • Demonstration of successful scale up from microliters at bench scale to 1000 liters in a GMP manufacturing environment.
Dec 411:30
Conference pass

Advances in the intratumoral administration of cancer agents

Keynotes
Dec 411:30
Conference pass

Best practices for outsourcing manufacture of biologics through CMOs

Keynotes
Dec 411:30
Conference pass

Generation of antibodies to novel targets

Keynotes
Dec 411:30
Conference pass

Managing process improvements for vaccines

Keynotes
Dec 411:30
Conference pass

Meet the investor: your questions answered

Keynotes
Dec 411:30
Conference pass

Strategies to improve patient stratification by interrogating the tumor microenvironment

Keynotes
Dec 411:30
Conference pass

The road map to NIH’s grant application process. How to find out more about the current programs available

Keynotes
Dec 414:30
Conference pass

A novel live attenuated RSV vaccine

Vaccine Development
Dec 414:30
Conference pass

CD40 agonists to enhance antigen presentation, resulting in improved quality and magnitude of T-cell responses

Cancer Antibodies and Small Molecules and Combinations
Dec 414:30
Conference pass

Designing cutting edge vaccine and biotechnology manufacturing platforms

Immunotherapy Bioprocessing, Manufacture & Delivery
*topic title TBC
Charles Heffernan, Former Supply Chain Transformation And Technology Innovation Lead, Gsk And Member, BioPhorum Operations Group
Dec 415:00
Conference pass

A novel WT1-targeting multivalent heteroclitic epitope immunotherapeutic: clinical update

Cancer Antibodies and Small Molecules and Combinations
· WT1 antigen biology· Overview of galinpepimut-S technology· Updates in galinpepimut-S clinical data· Upcoming phase 3 trial
Dec 415:30
Conference pass

Designing Immuno-Oncology trials to maximizing clinical outcomes and chances of success

Clinical Development
Dec 415:30
Conference pass

Leveraging bispecific molecules for the combination immunotherapy of cancer

Cancer Antibodies and Small Molecules and Combinations
Jon Wigginton, Chief Medical Officer And Senior Vice President Of Clinical Development, MacroGenics
Dec 416:30
Conference pass

Developing Antibody-Drug-Conjugates to unique embryonic cancer stem cell targets

Cancer Antibodies and Small Molecules and Combinations
Dec 417:00
Conference pass

Clinical development of next generation Antibody Drug Conjugates

Cancer Antibodies and Small Molecules and Combinations

Create your personal agenda –check the favourite icon

Dec 509:10
Conference pass
Dec 509:10
Conference pass

Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors

Engineered Cancer Therapies
Dec 509:10
Conference pass

Development of a versatile, single-injection vaccine formulation platform that can enhance immune response

Vaccine Delivery, Bioprocessing & Manufacture
Eric Appel, Assistant Professor of Material Science and Engineering, Stanford University
Dec 509:10
Conference pass
Dec 510:10
Conference pass

Experimental human challenge models used in respiratory track diseases and malaria

Clincal Development
Dec 510:10
Conference pass

Anti-Ebola mAbs currently being used in the Ebola outbreak in DRC

Infectious Disease Antibodies
Dec 510:25
Conference pass

A unique platform for research scale to mid-scale, host-independent biological manufacturing

Vaccine Delivery, Bioprocessing & Manufacture
Dec 511:10
Conference pass

Designing Immuno-Oncology trials to maximizing clinical outcomes and chances of success

Clincal Development
(Title TBC)
Dec 511:10
Conference pass

Targeting natural neoantigens through adoptive cellular therapies

Engineered Cancer Therapies
Dec 511:10
Conference pass

Monoclonal antibody development against infectious diseases in pediatric populations

Infectious Disease Antibodies
Dec 511:40
Conference pass

Identification of novel T-cell receptor targets and specificity profiling of TCRs tested in the clinic to develop safe & effective TCR therapies

Engineered Cancer Therapies
Dec 511:40
Conference pass

Challenges in vaccine manufacture in LMICs

Vaccine Delivery, Bioprocessing & Manufacture
Dec 511:40
Conference pass

Antibody-based therapy to combat Staphylococcus aureus infections

Infectious Disease Antibodies
Dec 512:10
Conference pass

Immuno-STAT – A novel platform for the selective modulation of antigen-specific T-cells

Engineered Cancer Therapies
Dec 512:10
Conference pass

Development of antibiotic drug conjugates

Infectious Disease Antibodies
Dec 514:20
Conference pass

Creating a public-private partnership to advance global health

Keynotes
Dec 514:50
Conference pass

Microbiome and epigenetic imprinting of immune responses to vaccination in humans

Keynotes
Dec 515:20
Conference pass

What will be the impact of moving towards earlier lines of therapy in cancer?

Keynotes
  • How will this change how we think about resistance?
  • What happens when we reach maximal amount of t-cell responses?
  • If immune capability decreases with subsequent lines of therapy is it a good idea to delay? Will investigational therapies preclude a patient from getting chemo?
  • Modifying the immune system to respond to immunotherapy
  • How does immunotherapy interact with radiation?
  • How will this affect drug candidate pipelines?
last published: 20/Aug/19 15:45 GMT

 
 
 

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com